Cohort study: 14% of adults aged 65 years or less who were infected with SARS-CoV-2 had at least one new type of clinical sequelae that required medical care after the acute phase of the illness.
Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study – The BMJ Editorial: Unpacking post-covid symptoms – The BMJ Commentary on Twitter (thread – click for more) After covid infections, 14% of >266,000 people, age ≤ 65, developed at least 1 sequelae that required medical care #LongCovid Just out […]
The post Cohort study: 14% of adults aged 65 years or less who were infected with SARS-CoV-2 had at least one new type of clinical sequelae that required medical care after the acute phase of the illness. appeared first on Links Medicus.
WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.
International COVID-19 trial to restart with focus on immune responses – Nature
The post WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19. appeared first on Links Medicus.
[Preprint] RECOVERY Trial: Colchicine does not improve outcomes in patients admitted to hospital with COVID-19.
Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv Commentary on Twitter (thread – click for more) RECOVERY pre-print: Colchicine 11340 patients hospitalised with COVID-19 Randomised to colchicine vs usual care No significant improvement in:– 28-day mortality– discharge alive at 28 days– progression to invasive mechanical […]
The post [Preprint] RECOVERY Trial: Colchicine does not improve outcomes in patients admitted to hospital with COVID-19. appeared first on Links Medicus.
Systematic review: Treatment of gastro-esophageal reflux disease to help manage asthma in adults and children may result in reduced use of rescue medications, but the benefits on the number of exacerbations and hospital utilization remain uncertain.
Pharmacological and surgical interventions for the treatment of gastro‐oesophageal reflux in adults and children with asthma – Cochrane Library Summary: Treatment of gastro-oesophageal reflux disease to help manage asthma in adults and children – Cochrane Library
The post Systematic review: Treatment of gastro-esophageal reflux disease to help manage asthma in adults and children may result in reduced use of rescue medications, but the benefits on the number of exacerbations and hospital utilization remain uncertain. appeared first on Links Medicus.
Opinion | E-Cigarettes and the U.S. Menthol Ban: A Missed Opportunity to Protect Youth.
E-Cigarettes and the U.S. Menthol Ban: A Missed Opportunity to Protect Youth – Think Global Health Commentary on Twitter (thread – click for more) ??? @US_FDA should ban flavors in all nicotine-containing products, not just menthol cigarettes. More than 8 out of 10 current youth e-cigarette users in the U.S. vape non-tobacco flavors. IHME […]
The post Opinion | E-Cigarettes and the U.S. Menthol Ban: A Missed Opportunity to Protect Youth. appeared first on Links Medicus.
Analysis: Where are we with drug treatments for covid-19?
Where are we with drug treatments for covid-19? – The BMJ
The post Analysis: Where are we with drug treatments for covid-19? appeared first on Links Medicus.
M-A: Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis – The incidence and mortality in the ICU were estimated to be 10.2% and 54.9%, respectively.
Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis: A systematic review and meta‐analysis – Mycoses
The post M-A: Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis – The incidence and mortality in the ICU were estimated to be 10.2% and 54.9%, respectively. appeared first on Links Medicus.
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy.
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy – EClinicalMedicine
The post SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. appeared first on Links Medicus.
COVID vaccines can block variant hitting Asia, lab study finds – “Assays using live SARS-CoV-2 offer hope that the vaccines made by Pfizer and Moderna will protect against a viral strain first seen in India”.
COVID vaccines can block variant hitting Asia, lab study finds – Nature See also: Pfizer, Moderna vaccines effective against Indian variants: study – MedicalXpress Commentary on Twitter Pfizer & Moderna mRNA vaccines are effective against multiple SARSCoV2 variants, including the B.1.617 & B.1.618, 2 variants underlying the surge in India. The research, while not […]
The post COVID vaccines can block variant hitting Asia, lab study finds – “Assays using live SARS-CoV-2 offer hope that the vaccines made by Pfizer and Moderna will protect against a viral strain first seen in India”. appeared first on Links Medicus.
#ACC21 – [Not published yet] RCT: Among hospitalized patients with Covid-19 and elevated D-Dimer, therapeutic anticoagulation with Rivaroxaban 20 mg was not associated with improved outcomes and resulted in increased major bleeding.
AntiCoagulaTIon cOroNavirus – ACTION – American College of Cardiology Commentary: ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19 – TCTMD Video: Dr. Renato Lopes and Dr. C. Michael Gibson Discuss: Randomized Clinical Trial To Evaluate A Routine Full Anticoagulation Strategy In Patients With Coronavirus Infection (SARS-CoV-2) Admitted To Hospital: The Coalition ACTION Trial
The post #ACC21 – [Not published yet] RCT: Among hospitalized patients with Covid-19 and elevated D-Dimer, therapeutic anticoagulation with Rivaroxaban 20 mg was not associated with improved outcomes and resulted in increased major bleeding. appeared first on Links Medicus.